molybdenum has been researched along with Lassitude in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Antonarakis, ES; Beer, TM; Callahan, JA; Carducci, MA; Gordon, G; Lin, J; Mathew, P; Morris, M; Reich, SD; Ryan, CJ; Wilding, G; Zahurak, M | 1 |
1 trial(s) available for molybdenum and Lassitude
Article | Year |
---|---|
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Topics: Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatigue; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Molybdenum; Nausea; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Superoxide Dismutase; Time Factors; Treatment Outcome | 2013 |